Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Non-small cell lung cancer in countries of Central and Southeastern Europe : diagnostic procedures and treatment reimbursement surveyed by the Central European Cooperative Oncology Group
Avtorji:ID Ryška, Ales (Avtor)
ID Buiga, Rares (Avtor)
ID Fakirova, Albena (Avtor)
ID Kern, Izidor, Klinika Golnik (Avtor)
ID Olszewski, Włodzimierz (Avtor)
ID Plank, Lukas (Avtor)
ID Seiwerth, Sven (Avtor)
ID Toth, Erika (Avtor)
ID Zivka, Eri (Avtor)
ID Thallinger, Christiane (Avtor)
ID Zielinski, Christoph (Avtor)
ID Brčić, Luka (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite http://theoncologist.alphamedpress.org/content/23/12/e152
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:This article analyzes the availability of different diagnostic procedures of non-small cell lung cancer (NSCLC) and the reimbursement landscape of drugs for NSCLC in countries of central and southeastern Europe (CEE). A survey was conducted by the Central European Cooperative Oncology Group. Results of the survey show that both availability and reimbursement of diagnoses of molecular alterations in NSCLC, the detection of which is essential for therapeutic decisions, varies widely between countries of CEE. Not only is "reflex" testing often substituted by analyses performed only "on demand," but reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. It was concluded that a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. Implications for Practice. This article provides an overview of the limitations in lung cancer treatment in countries of central and southeastern Europe, as well as the reimbursement status of various lung cancer treatment regimens in these countries, which directly impacts treatment options.
Ključne besede:Non-small cell lung carcinoma -- diagnosis -- economics -- Europe, molecular diagnostic techniques, precision medicine, Central Europe, Southeastern Europe, reimbursement
Leto izida:2018
Status objave pri reviji:Objavljeno
Verzija članka:Založnikova različica članka
Založnik:AlphaMed Press
Št. strani:str. e152-e158
Številčenje:Vol. 23, no. 12
Izvor:ZDA
PID:20.500.12556/DiRROS-12621 Novo okno
UDK:616-006
ISSN pri članku:1549-490X
DOI:10.1634/theoncologist.2018-0008 Novo okno
COBISS.SI-ID:2048460913 Novo okno
Avtorske pravice:©AlphaMed Press 2018
Opomba:Soavtor iz Slovenije: Izidor Kern; Nasl. z nasl. zaslona; Opis vira z dne 27. 3. 2019;
Datum objave v DiRROS:09.11.2020
Število ogledov:1026
Število prenosov:221
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:AddThis
AddThis uporablja piškotke, za katere potrebujemo vaše privoljenje.
Uredi privoljenje...

Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:The oncologist
Skrajšan naslov:Oncologist
Založnik:AlphaMed Press
ISSN:1549-490X
COBISS.SI-ID:521539609 Novo okno

Sekundarni jezik

Jezik:Ni določen
Ključne besede:nedrobnocelični karcinom pljuč -- diagnostika -- ekonomika -- Evropa, molekularne diagnostične tehnike, personalizirana medicina, srednja Evropa, jugovzhodna Evropa, povračilo stroškov


Nazaj